Abstract
Each year, rotavirus gastroenteritis (RG) results in 25 million clinic visits, 2 million hospitalizations, and 600,000 deaths in young children worldwide, mostly in developing countries. The first rotavirus vaccine, Rotashield, was licensed and approved for routine immunization in the U.S. in 1998 but was soon withdrawn because of an association with intussusception. Two other rotavirus vaccines have since demonstrated safety, immunogenicity, and protection, but larger studies were required to eliminate the possibility of vaccine-associated intussusception. Now, researchers have examined the efficacy and safety of these vaccines in large-scale, company-sponsored trials. …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
